The State of Digital Recovery Funding in 2026: Quiet Year, Selective Bets

After Pear Therapeutics’ 2023 bankruptcy — the digital therapeutics company whose FDA-approved SUD app could not achieve insurance reimbursement — the entire addiction-tech category went through a re-rating. Three years in, the recalibration looks complete, and the surviving model is clearer.

Crunchbase News tracked the headline rounds in late 2025 and early 2026: Pelago raised $58M in a Series C in March, bringing total funding to $137M. Boulder Care raised $35M in its most recent round. Nashville-based Wayspring secured roughly $45M led by CVS Health Ventures. All three operate as virtual clinics with billable services — they are not pure software plays.

Tracxn counts 54 teleconsultation de-addiction startups globally as of April 2026, of which 19 have raised institutional funding and 12 have crossed Series A. That is a substantially smaller cohort than the late-2021 boom — and a much more focused one. Investors are funding companies that can either bill insurance, hold a value-based contract with a payer, or demonstrate measurable outcomes a public-sector buyer will pay for.

Government money is filling part of the gap

In February, the UK’s Department of Health and Social Care announced a £20M fund for digital addiction tech, specifically targeting craving-management apps, mood tracking, and peer-connection tools. The U.S. parallel runs through NIDA’s recurring $100K SUD Startup Challenge, NIH HEAL Initiative grants, and SAMHSA technology line items in the FY 2026 NOFO forecast.

It is a different funding mix than 2021 — less Tiger Global, more state grant administrators — and it pulls toward different products. Tools that work for Medicaid populations, tools that integrate with state behavioral health infrastructure, tools that produce auditable outcome data. The investors at Rock Health and General Catalyst Health have been explicit that this is the post-Pear thesis.

What this means for anyone building or evaluating addiction tech today

Three things, briefly. First, single-revenue-stream products — particularly those dependent on a prescription and a specific insurance pathway — still carry the risk Pear demonstrated; the smart capital is asking about diversification on day one. Second, the gap between “FDA-cleared” and “covered” remains wide and is unlikely to narrow in the current CMS environment. Third, the public-sector funding side is where the new dollars are flowing, especially for products that improve navigation, outcomes tracking, and continuity of care — three areas where the field has been chronically underserved.

For anyone considering a recovery app or digital tool today: ask who pays, ask whether the product would work if the prescription pathway closed, and ask what outcomes the team is measuring. Those three questions sort the durable from the speculative more reliably than any specific feature comparison.